Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Más filtros











Intervalo de año de publicación
1.
Arch. argent. pediatr ; 117(4): 413-415, ago. 2019.
Artículo en Español | LILACS, BINACIS | ID: biblio-1054947

RESUMEN

La hipertensión pulmonar es una complicación frecuente de la displasia broncopulmonar. A pesar de su alta incidencia, existen pocos tratamientos disponibles. El epoprostenol y el treprostinil son análogos de las prostaglandinas I2, que activan la adenilato ciclasa e incrementan el adenosín monofosfato cíclico en las células de la musculatura lisa de la arteria pulmonar y pueden resultar eficaces en el tratamiento de estos pacientes. Se presenta el caso de un prematuro de extremado bajo peso con hipertensión pulmonar secundaria a displasia broncopulmonar grave, no respondedora a óxido nítrico inhalado y sildenafilo, que fue tratado con análogos de prostaglandinas I2. En nuestro paciente, este tratamiento evidenció mejoría clínica y ecocardiográfica significativa tras varias semanas de tratamiento.


Pulmonary hypertension is a common complication of bronchopulmonary dysplasia, with a high mortality rate. Despite the high incidence of pulmonary hypertension, there are few available treatments. Epoprostenol and treprostinil are prostaglandin I2 analogs that activate adenylate cyclase and increase cyclic adenosine monophosphate in the pulmonary arterial smooth muscle cells. Therefore, they may be an effective treatment for these patients. We report the use of prostaglandin I2 analogs in an extremely low birth weight preterm baby with severe bronchopulmonary dysplasia associated with pulmonary hypertension non-responding to inhaled nitric oxide and sildenafil. In our patient this treatment resulted in remarkable clinical and echocardiographic improvement, evident after a few weeks of treatment.


Asunto(s)
Humanos , Masculino , Recién Nacido , Displasia Broncopulmonar/complicaciones , Hipertensión Pulmonar/diagnóstico , Traqueostomía , Epoprostenol/uso terapéutico , Recien Nacido Extremadamente Prematuro , Hipertensión Pulmonar/tratamiento farmacológico
2.
Arch Argent Pediatr ; 117(4): e413-e415, 2019 08 01.
Artículo en Español | MEDLINE | ID: mdl-31339286

RESUMEN

Pulmonary hypertension is a common complication of bronchopulmonary dysplasia, with a high mortality rate. Despite the high incidence of pulmonary hypertension, there are few available treatments. Epoprostenol and treprostinil are prostaglandin I2 analogs that activate adenylate cyclase and increase cyclic adenosine monophosphate in the pulmonary arterial smooth muscle cells. Therefore, they may be an effective treatment for these patients. We report the use of prostaglandin I2 analogs in an extremely low birth weight preterm baby with severe bronchopulmonary dysplasia associated with pulmonary hypertension non-responding to inhaled nitric oxide and sildenafil. In our patient this treatment resulted in remarkable clinical and echocardiographic improvement, evident after a few weeks of treatment.


La hipertensión pulmonar es una complicación frecuente de la displasia broncopulmonar. A pesar de su alta incidencia, existen pocos tratamientos disponibles. El epoprostenol y el treprostinil son análogos de las prostaglandinas I2, que activan la adenilato ciclasa e incrementan el adenosín monofosfato cíclico en las células de la musculatura lisa de la arteria pulmonar y pueden resultar eficaces en el tratamiento de estos pacientes. Se presenta el caso de un prematuro de extremado bajo peso con hipertensión pulmonar secundaria a displasia broncopulmonar grave, no respondedora a óxido nítrico inhalado y sildenafilo, que fue tratado con análogos de prostaglandinas I2. En nuestro paciente, este tratamiento evidenció mejoría clínica y ecocardiográfica significativa tras varias semanas de tratamiento.


Asunto(s)
Antihipertensivos/uso terapéutico , Displasia Broncopulmonar/complicaciones , Epoprostenol/análogos & derivados , Epoprostenol/uso terapéutico , Hipertensión Pulmonar/tratamiento farmacológico , Hipertensión Pulmonar/etiología , Humanos , Recien Nacido con Peso al Nacer Extremadamente Bajo , Recién Nacido , Masculino
3.
Clín. salud ; 30(1): 21-31, mar. 2019.
Artículo en Español | IBECS | ID: ibc-180395

RESUMEN

Los bebés expuestos a altos niveles de ansiedad materna durante la etapa prenatal pueden desarrollar un eje HPA (hipotálamo pituitario adrenal) más reactivo, lo que supone vulnerabilidad a padecer psicopatologías. En este estudio prospectivo investigamos las relaciones entre la ansiedad prenatal maternal, el desarrollo psicológico infantil y la reactividad del eje HPA en bebés de 2 a 3 meses. Recogimos datos de cuarenta y seis díadas de madres y bebés. El análisis principal no reveló relaciones significativas entre las tres variables estudiadas, pero la variabilidad apuntó a que la ansiedad materna prenatal podría asociarse a efectos diferenciales en la reactividad del eje HPA en función del desarrollo psicológico infantil. Además, los resultados indicaron que las madres con ansiedad prenatal presentaban otros síntomas psicopatológicos, como sensibilidad interpersonal (p < .001) y obsesión-compulsión (p < .001). Esto es significativo para futuras investigaciones y a nivel clínico para promover intervenciones psicológicas durante la gestación


Babies exposed to high levels of maternal anxiety during the prenatal period may develop a more reactive HPA (hypothalamic-pituitary-adrenal) axis, which poses a vulnerability to psychopathology. In this prospective study, we investigated the relationships between antenatal maternal anxiety, infant psychological developmen,t and HPA axis reactivity in 2 to 3-month-old babies. We use data from forty-six mother-child dyads. The main analysis did not reveal significant relationships between the variables studied, but the variability pointed out that antenatal maternal anxiety could be associated with differential effects on the reactivity of the HPA axis according to the child’s psychological development. In addition, the results indicated that mothers with prenatal anxiety presented other psychopathological symptoms, such as interpersonal sensitivity (p < .001) and obsession-compulsion (p < .001). This is significant for future research and - at a clinical level - to promote psychological interventions during pregnancy


Asunto(s)
Humanos , Masculino , Femenino , Lactante , Sistema Hipotálamo-Hipofisario/fisiología , Trastornos de Ansiedad/fisiopatología , Desarrollo Fetal/fisiología , Hidrocortisona , Efectos Tardíos de la Exposición Prenatal/fisiopatología , Desarrollo Infantil/fisiología
4.
Front Neurosci ; 10: 323, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-27462203

RESUMEN

Hypothermia is a standard treatment for neonatal encephalopathy, but nearly 50% of treated infants have adverse outcomes. Pharmacological therapies can act through complementary mechanisms with hypothermia improving neuroprotection. Cannabidiol could be a good candidate. Our aim was to test whether immediate treatment with cannabidiol and hypothermia act through complementary brain pathways in hypoxic-ischemic newborn piglets. Hypoxic-ischemic animals were randomly divided into four groups receiving 30 min after the insult: (1) normothermia and vehicle administration; (2) normothermia and cannabidiol administration; (3) hypothermia and vehicle administration; and (4) hypothermia and cannabidiol administration. Six hours after treatment, brains were processed to quantify the number of damaged neurons by Nissl staining. Proton nuclear magnetic resonance spectra were obtained and analyzed for lactate, N-acetyl-aspartate and glutamate. Metabolite ratios were calculated to assess neuronal damage (lactate/N-acetyl-aspartate) and excitotoxicity (glutamate/Nacetyl-aspartate). Western blot studies were performed to quantify protein nitrosylation (oxidative stress), content of caspase-3 (apoptosis) and TNFα (inflammation). Individually, the hypothermia and the cannabidiol treatments reduced the glutamate/Nacetyl-aspartate ratio, as well as TNFα and oxidized protein levels in newborn piglets subjected to hypoxic-ischemic insult. Also, both therapies reduced the number of necrotic neurons and prevented an increase in lactate/N-acetyl-aspartate ratio. The combined effect of hypothermia and cannabidiol on excitotoxicity, inflammation and oxidative stress, and on cell damage, was greater than either hypothermia or cannabidiol alone. The present study demonstrated that cannabidiol and hypothermia act complementarily and show additive effects on the main factors leading to hypoxic-ischemic brain damage if applied shortly after the insult.

5.
J Neuroinflammation ; 8(1): 5, 2011 Jan 18.
Artículo en Inglés | MEDLINE | ID: mdl-21244691

RESUMEN

BACKGROUND: The phytocannabinoid cannabidiol (CBD) exhibits antioxidant and antiinflammatory properties. The present study was designed to explore its effects in a mouse model of sepsis-related encephalitis by intravenous administration of lipopolysaccharide (LPS). METHODS: Vascular responses of pial vessels were analyzed by intravital microscopy and inflammatory parameters measured by qRT-PCR. RESULTS: CBD prevented LPS-induced arteriolar and venular vasodilation as well as leukocyte margination. In addition, CBD abolished LPS-induced increases in tumor necrosis factor-alpha and cyclooxygenase-2 expression as measured by quantitative real time PCR. The expression of the inducible-nitric oxide synthase was also reduced by CBD. Finally, preservation of Blood Brain Barrier integrity was also associated to the treatment with CBD. CONCLUSIONS: These data highlight the antiinflammatory and vascular-stabilizing effects of CBD in endotoxic shock and suggest a possible beneficial effect of this natural cannabinoid.


Asunto(s)
Vasos Sanguíneos/efectos de los fármacos , Vasos Sanguíneos/patología , Cannabidiol , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Lipopolisacáridos/farmacología , Piamadre/irrigación sanguínea , Animales , Barrera Hematoencefálica/efectos de los fármacos , Barrera Hematoencefálica/fisiología , Encéfalo , Cannabidiol/farmacología , Cannabidiol/uso terapéutico , Circulación Cerebrovascular/efectos de los fármacos , Ciclooxigenasa 2/genética , Ciclooxigenasa 2/metabolismo , Inflamación/patología , Leucocitos/citología , Leucocitos/fisiología , Ratones , Ratones Endogámicos C57BL , Microscopía/métodos , Óxido Nítrico Sintasa de Tipo II/genética , Óxido Nítrico Sintasa de Tipo II/metabolismo , Estrés Oxidativo , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/metabolismo
6.
Stroke ; 41(12): 2956-64, 2010 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-21115947

RESUMEN

BACKGROUND AND PURPOSE: The endocannabinoid system has been involved in the modulation of neural stem cells proliferation, survival and differentiation as well as in the generation of new oligodendrocyte progenitors in the postnatal brain. The present work aims to test the effect of the synthetic Type 1 and Type 2 cannabinoid receptor agonist WIN55212-2 on these processes in the context of neonatal rat brain hypoxia-ischemia (HI). METHODS: P7 Wistar rats were subjected to HI and treated either with WIN55212-2 (1 mg/kg) or vehicle twice daily for 7 days after HI and euthanized at 1, 2, 7, 14, or 28 days to explore white matter injury progression and the neurogenic response in the subventricular zone after HI. RESULTS: Our findings reveal that WIN55212-2 promotes remyelination of the injured external capsule, increasing the number of NG2+ early oligodendrocyte progenitors 7 days after HI in this area and the number of APC+ mature oligodendrocytes in the injured striatum 14 and 28 days after HI. WIN55212-2 also increases cell proliferation and protein expression of the neuroblast marker doublecortin in the subventricular zone 7 days after neonatal HI as well as the number of newly generated neuroblasts (5-bromodeoxyuridine+/doublecortin+ cells) in the ipsilateral striatum 14 days after HI. CONCLUSIONS: Our results suggest that the activation of the endocannabinoid system promotes white and gray matter recovery after neonatal HI injury.


Asunto(s)
Animales Recién Nacidos/fisiología , Benzoxazinas/uso terapéutico , Hipoxia-Isquemia Encefálica/tratamiento farmacológico , Morfolinas/uso terapéutico , Naftalenos/uso terapéutico , Regeneración Nerviosa/efectos de los fármacos , Receptores de Cannabinoides/efectos de los fármacos , Animales , Antimetabolitos , Western Blotting , Encéfalo/patología , Bromodesoxiuridina , Recuento de Células , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Cuerpo Estriado/citología , Cuerpo Estriado/efectos de los fármacos , Proteína Doblecortina , Femenino , Técnica del Anticuerpo Fluorescente , Hipoxia-Isquemia Encefálica/patología , Inmunohistoquímica , Oligodendroglía/efectos de los fármacos , Embarazo , Ratas , Ratas Wistar , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA